Polypharmacology of dopamine D1-like receptor antagonists
Polifarmakologija antagonista dopaminskih D1-receptora
Abstract
Drug discovery based on development of selective ligands for a specific target intended to modulate its activity and revert pathophysiological process is now recognized as too simplistic to design effective agent for complex multifactorial diseases, characterized by diverse physiological dysfunctions caused by deregulations of complex networks of proteins. Major challenge in modern drug discovery is to rationally design multitarget drugs able to specifically modulate only a group of desired targets while minimizing interactions with off-targets. Multifactorial cerebral mechanisms implicated in mental (psychiatrics) and neurodegenerative diseases and interactions of the neurotransmitter systems are two main reasons for applying polypharmacology ('multi-target') strategy in drug discovery for these complex brain diseases. In this paper we review polypharmacological profile and potential therapeutic application of dopamine D1-like receptor antagonists.
Istraživanje novih lekova koji deluju kao selektivni ligandi za određeno ciljno mesto i tako usporavaju ili zaustavljaju patofiziološki process danas se smatra nedovoljno efikasnim u razvoju lekova za kompleksna oboljenja nastala usled više patofizioloških procesa i promena u nekoliko signalnih puteva. Najveći izazov predstavlja razvoj lekova koji specifično modifikuju aktivnost nekoliko izabranih ciljnih mesta dejstva, a istovremeno minimalno stupaju u interakciju sa ostalim biomolekulima. Kompleksni patofiziološki procesi psihijatrijskih i neurodegenerativnih oboljenja i interakcija neurotransmiterskih sistema su dva ključna razloga za primenu strategije polifarmakologije (strategije multiplih ciljnih mesta) u razvoju efikasnih lekova koji deluju na centralni nervni sistem. U ovom radu dat je pregled polifarmakoloških profila i potencijalne terapijske primene antagonista receptora koji pripadaju D1 familiji dopaminskih receptora.
Keywords:
polypharmacology / multitarget drugs / dopamine receptors / polifarmakologija / multitarget lekovi / dopaminski receptoriSource:
Arhiv za farmaciju, 2015, 65, 5, 287-303Publisher:
- Savez farmaceutskih udruženja Srbije, Beograd
Funding / projects:
- Synthesis, Quantitative Structure and Activity Relationship, Physico-Chemical Characterisation and Analysis of Pharmacologically Active Substances (RS-MESTD-Basic Research (BR or ON)-172033)
Collections
Institution/Community
PharmacyTY - JOUR AU - Nikolić, Katarina AU - Filipić, Slavica AU - Agbaba, Danica PY - 2015 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2499 AB - Drug discovery based on development of selective ligands for a specific target intended to modulate its activity and revert pathophysiological process is now recognized as too simplistic to design effective agent for complex multifactorial diseases, characterized by diverse physiological dysfunctions caused by deregulations of complex networks of proteins. Major challenge in modern drug discovery is to rationally design multitarget drugs able to specifically modulate only a group of desired targets while minimizing interactions with off-targets. Multifactorial cerebral mechanisms implicated in mental (psychiatrics) and neurodegenerative diseases and interactions of the neurotransmitter systems are two main reasons for applying polypharmacology ('multi-target') strategy in drug discovery for these complex brain diseases. In this paper we review polypharmacological profile and potential therapeutic application of dopamine D1-like receptor antagonists. AB - Istraživanje novih lekova koji deluju kao selektivni ligandi za određeno ciljno mesto i tako usporavaju ili zaustavljaju patofiziološki process danas se smatra nedovoljno efikasnim u razvoju lekova za kompleksna oboljenja nastala usled više patofizioloških procesa i promena u nekoliko signalnih puteva. Najveći izazov predstavlja razvoj lekova koji specifično modifikuju aktivnost nekoliko izabranih ciljnih mesta dejstva, a istovremeno minimalno stupaju u interakciju sa ostalim biomolekulima. Kompleksni patofiziološki procesi psihijatrijskih i neurodegenerativnih oboljenja i interakcija neurotransmiterskih sistema su dva ključna razloga za primenu strategije polifarmakologije (strategije multiplih ciljnih mesta) u razvoju efikasnih lekova koji deluju na centralni nervni sistem. U ovom radu dat je pregled polifarmakoloških profila i potencijalne terapijske primene antagonista receptora koji pripadaju D1 familiji dopaminskih receptora. PB - Savez farmaceutskih udruženja Srbije, Beograd T2 - Arhiv za farmaciju T1 - Polypharmacology of dopamine D1-like receptor antagonists T1 - Polifarmakologija antagonista dopaminskih D1-receptora VL - 65 IS - 5 SP - 287 EP - 303 DO - 10.5937/arhfarm1505287N ER -
@article{ author = "Nikolić, Katarina and Filipić, Slavica and Agbaba, Danica", year = "2015", abstract = "Drug discovery based on development of selective ligands for a specific target intended to modulate its activity and revert pathophysiological process is now recognized as too simplistic to design effective agent for complex multifactorial diseases, characterized by diverse physiological dysfunctions caused by deregulations of complex networks of proteins. Major challenge in modern drug discovery is to rationally design multitarget drugs able to specifically modulate only a group of desired targets while minimizing interactions with off-targets. Multifactorial cerebral mechanisms implicated in mental (psychiatrics) and neurodegenerative diseases and interactions of the neurotransmitter systems are two main reasons for applying polypharmacology ('multi-target') strategy in drug discovery for these complex brain diseases. In this paper we review polypharmacological profile and potential therapeutic application of dopamine D1-like receptor antagonists., Istraživanje novih lekova koji deluju kao selektivni ligandi za određeno ciljno mesto i tako usporavaju ili zaustavljaju patofiziološki process danas se smatra nedovoljno efikasnim u razvoju lekova za kompleksna oboljenja nastala usled više patofizioloških procesa i promena u nekoliko signalnih puteva. Najveći izazov predstavlja razvoj lekova koji specifično modifikuju aktivnost nekoliko izabranih ciljnih mesta dejstva, a istovremeno minimalno stupaju u interakciju sa ostalim biomolekulima. Kompleksni patofiziološki procesi psihijatrijskih i neurodegenerativnih oboljenja i interakcija neurotransmiterskih sistema su dva ključna razloga za primenu strategije polifarmakologije (strategije multiplih ciljnih mesta) u razvoju efikasnih lekova koji deluju na centralni nervni sistem. U ovom radu dat je pregled polifarmakoloških profila i potencijalne terapijske primene antagonista receptora koji pripadaju D1 familiji dopaminskih receptora.", publisher = "Savez farmaceutskih udruženja Srbije, Beograd", journal = "Arhiv za farmaciju", title = "Polypharmacology of dopamine D1-like receptor antagonists, Polifarmakologija antagonista dopaminskih D1-receptora", volume = "65", number = "5", pages = "287-303", doi = "10.5937/arhfarm1505287N" }
Nikolić, K., Filipić, S.,& Agbaba, D.. (2015). Polypharmacology of dopamine D1-like receptor antagonists. in Arhiv za farmaciju Savez farmaceutskih udruženja Srbije, Beograd., 65(5), 287-303. https://doi.org/10.5937/arhfarm1505287N
Nikolić K, Filipić S, Agbaba D. Polypharmacology of dopamine D1-like receptor antagonists. in Arhiv za farmaciju. 2015;65(5):287-303. doi:10.5937/arhfarm1505287N .
Nikolić, Katarina, Filipić, Slavica, Agbaba, Danica, "Polypharmacology of dopamine D1-like receptor antagonists" in Arhiv za farmaciju, 65, no. 5 (2015):287-303, https://doi.org/10.5937/arhfarm1505287N . .